Yuta Ikio1,2, Akira Sagari3, Akira Nakashima2, Daiki Matsuda1,2, Terumitsu Sawai2, Toshio Higashi4. 1. Department of Rehabilitation, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan. 2. Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan. 3. School of Health Sciences, Faculty of Medicine, Shinshu University, Nagano, Japan. 4. Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan. higashi-t@nagasaki-u.ac.jp.
Abstract
PURPOSE: Previous evidence regarding the impact of exercise interventions on chemotherapy-induced peripheral neuropathy often focuses on lower-extremity functions, such as muscle strength and balance ability, while their effects on upper extremities remain unknown. We aimed to evaluate the efficacy of combined hand exercise intervention on upper-extremity function, symptoms, and quality-of-life in patients with chemotherapy-induced peripheral neuropathy (CIPN). METHODS: After screening 341 patients, 42 were randomly assigned to either the intervention (n = 21) or control (n = 21) group. Participants were evaluated at baseline (T0) and after one (T1) and two (T2) chemotherapy cycles. The primary outcome was upper-extremity function measured using the Michigan Hand Outcomes Questionnaire (MHQ) at T2. The intention-to-treat and as-treated populations were compared using a mixed-effect model. RESULTS: In the intention-to-treat analysis, the decline in activities of daily living of MHQ was significantly suppressed in the intervention group compared with that in the control group at T2 (difference: 7.23; 95% confidence interval: 0.35-14.10). Similarly, in the as-treated analysis, the decline in activities of daily living of MHQ was significantly suppressed in the intervention group compared with that in the control group at T2 (difference: 13.09; 95% confidence interval: 5.68-20.49). Pain also significantly improved in the intervention group compared with that in the control group at T2 (difference: 13.21; 95% confidence interval: - 22.91 to - 3.51). CONCLUSION: The combined hand exercise intervention may improve upper-extremity function, such as by suppressing decline in ADL, and reduce pain in patients with CIPN.
PURPOSE: Previous evidence regarding the impact of exercise interventions on chemotherapy-induced peripheral neuropathy often focuses on lower-extremity functions, such as muscle strength and balance ability, while their effects on upper extremities remain unknown. We aimed to evaluate the efficacy of combined hand exercise intervention on upper-extremity function, symptoms, and quality-of-life in patients with chemotherapy-induced peripheral neuropathy (CIPN). METHODS: After screening 341 patients, 42 were randomly assigned to either the intervention (n = 21) or control (n = 21) group. Participants were evaluated at baseline (T0) and after one (T1) and two (T2) chemotherapy cycles. The primary outcome was upper-extremity function measured using the Michigan Hand Outcomes Questionnaire (MHQ) at T2. The intention-to-treat and as-treated populations were compared using a mixed-effect model. RESULTS: In the intention-to-treat analysis, the decline in activities of daily living of MHQ was significantly suppressed in the intervention group compared with that in the control group at T2 (difference: 7.23; 95% confidence interval: 0.35-14.10). Similarly, in the as-treated analysis, the decline in activities of daily living of MHQ was significantly suppressed in the intervention group compared with that in the control group at T2 (difference: 13.09; 95% confidence interval: 5.68-20.49). Pain also significantly improved in the intervention group compared with that in the control group at T2 (difference: 13.21; 95% confidence interval: - 22.91 to - 3.51). CONCLUSION: The combined hand exercise intervention may improve upper-extremity function, such as by suppressing decline in ADL, and reduce pain in patients with CIPN.
Authors: Charles L Loprinzi; Christina Lacchetti; Jonathan Bleeker; Guido Cavaletti; Cynthia Chauhan; Daniel L Hertz; Mark R Kelley; Antoinette Lavino; Maryam B Lustberg; Judith A Paice; Bryan P Schneider; Ellen M Lavoie Smith; Mary Lou Smith; Thomas J Smith; Nina Wagner-Johnston; Dawn L Hershman Journal: J Clin Oncol Date: 2020-07-14 Impact factor: 44.544
Authors: Marta Seretny; Gillian L Currie; Emily S Sena; Sabrina Ramnarine; Robin Grant; Malcolm R MacLeod; Leslie A Colvin; Marie Fallon Journal: Pain Date: 2014-09-23 Impact factor: 6.961
Authors: Rebecca M Speck; Angela DeMichele; John T Farrar; Sean Hennessy; Jun J Mao; Margaret G Stineman; Frances K Barg Journal: Support Care Cancer Date: 2012-01-11 Impact factor: 3.603
Authors: Sarah Prinsloo; Diane Novy; Larry Driver; Randall Lyle; Lois Ramondetta; Cathy Eng; Jennifer McQuade; Gabriel Lopez; Lorenzo Cohen Journal: Cancer Date: 2017-03-03 Impact factor: 6.860
Authors: Ian R Kleckner; Charles Kamen; Jennifer S Gewandter; Nimish A Mohile; Charles E Heckler; Eva Culakova; Chunkit Fung; Michelle C Janelsins; Matthew Asare; Po-Ju Lin; Pavan S Reddy; Jeffrey Giguere; Jeffrey Berenberg; Shelli R Kesler; Karen M Mustian Journal: Support Care Cancer Date: 2017-12-14 Impact factor: 3.603
Authors: Nicole P M Ezendam; Brenda Pijlman; Celine Bhugwandass; Johannes F M Pruijt; Floortje Mols; M Caroline Vos; Johanna M A Pijnenborg; Lonneke V van de Poll-Franse Journal: Gynecol Oncol Date: 2014-09-30 Impact factor: 5.482
Authors: Philipp Zimmer; Sina Trebing; Ursula Timmers-Trebing; Alexander Schenk; Rainer Paust; Wilhelm Bloch; Roland Rudolph; Fiona Streckmann; Freerk T Baumann Journal: Support Care Cancer Date: 2017-09-30 Impact factor: 3.603